Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SBP GROUP CCR8 Monoclonal Antibody for Gastric Cancer Completes First Patient Enrollment in Clinical Trial
Recommend 21 Positive 30 Negative 9 |
||||
|
||||
|
SBP GROUP (01177.HK) announced that the first patient has been successfully enrolled in a Phase III registrational clinical trial of cafelkibart “CCR8 Monoclonal Antibody” (development code: LM-108), a national Category 1 innovative drug independently developed by LaNova Medicines Limited (LaNova Medicines), a wholly-owned subsidiary of the Group. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
